Saratin, an inhibitor of collagen-platelet interaction, decreases venous anastomotic intimal hyperplasia in a canine dialysis access model

Vascular and Endovascular Surgery

Volumn 37, Issue 4, 2003, Pages 259-269

  Smith, Todd P ^a,b   Alshafie, Tarek A ^a,b   Cruz, Carlos P ^a,b   Fan, Chun Yang ^c   Brown, Aliza T ^a,b   Wang, Yunfang ^a   Eidt, John F ^a,b   Moursi, Mohammed M ^a,b  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; HEMATOLOGIC AGENT; POLITEF; SARATIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DIALYSIS; DOG; FEMALE; GRAFT REJECTION; HYPERPLASIA; INTIMA; MORPHOMETRICS; NONHUMAN; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; VEIN ANASTOMOSIS; VEIN BLOOD FLOW;

EID: 0042767753     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/153857440303700405     Document Type: Article

References (30)

1. United States Renal Data System Internet Site (www.usrds.org)
2. Feldman HIKS, Wasserstein A: Hemodialysis vascular access morbidity. J Am Soc Nephrol 7:523-535, 1996.
3. Windus DW: Permanent vascular access: A nephrologist's view. Am J Kidney Dis 21:457-471, 1993.
4. Hodges TC, Fillinger MF, Zwolak RM, et al: Longitudinal comparison of dialysis access methods: Risk factors for failure. J Vasc Surg 26:1009-1019, 1997.
5. Schwab SJ, Harrington JT, Singh A, et al: Vascular access for hemodialysis. Kidney Int 55:2078-2090, 1999.
6. Chazon JA, London MR, Pono LM: Long-term survival of vascular accesses in a large chronic hemodialysis population. Nephron 69:228-233, 1995.
7. Sreedhara R, Himmelfarb J, Lazarus JM, et al: Antiplatelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int 45:1477-1483, 1994.
8. Beathard GA: The treatment of vascular access dysfunction: A nephrologist's view and experience. Adv Ren Replace Ther 1:131-147, 1994.
9. Himmelfrab J, Saad T: Hemodialysis vascular access: Emerging concepts. Curr Opin Nephrol Hyperten 5:484-491, 1996.
10. Roy-Chaudhury P, Kelly BS, Miller MA, et al: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 59:2325-2334, 2001.
11. Tyrrell MR, Wolfe JHN: New prosthetic venous collar anastomotic technique: Combining the best of other procedures. Br J Surg 78:1016-1017, 1991.
12. Barnes CS, Krafft B, Frech M, et al: Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen. Semin Thromb Hemost 27:337-347, 2001.
13. Cruz CP, Eidt JF, Drouilhet JC, et al: Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg 34:724-729, 2001.
14. Lumsden AB, Chen C, Ku DN: Neovascularization in the venous neointimal hyperplastic lesions of arteriovenous grafts (abstract). J Am Soc Nephrol 5:421, 1994.
15. Law MM, Gelabert HA, Moore WS, et al: Cigarette smoking increases the development of intimal hyperplasia after vascular injury. J Vasc Surg 23:401-409, 1996.
16. Baker LD Jr, Johnson JM, Goldfarb D: Expanded polytetrafluoroethylene (PTFE) subcutaneous arteriovenous conduit: An improved vascular access for chronic hemodialysis. ASAIO Trans 22:382-387, 1976.
17. Palder SE, Kirkman RL, Whittemore AD, et al: Vascular access for hemodialysis. Ann Surg 202:235-239, 1986.
18. Bell DD, Rosenthal JJ: Arteriovenous graft life in chronic hemodialysis. Arch Surg 123:1169-1172, 1988.
19. Zwolak RM, Adams MC, Clowes AW: Kinetics of vein graft hyperplasia: Association with tangential stress. J Vasc Surg 5:126, 1987.
20. Fingerle J, Johnson R, Clowes AW, et al: Role of platelets in smooth muscle cell proliferation and migration after vascular surgery in rat carotid artery. Proc Natl Acad Sci USA 86:8412-8416, 1989.
21. Kraiss LW, Clowes AW: Response of the arterial wall to injury and intimal hyperplasia. In: The Basic Science of Vascular Disease, ed. 1, ed. by Sidawy AN, Sumpio BE, DePalma RG. Armonk, NY: Futura, 1997, pp 289-317.
22. Schwartz L, Bourassa MG, Lesperance J: Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 318:1714-1719, 1988.
23. 2 blockade on clinical outcome and restenosis after successful coronary angioplasty: Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART-II). Circulation 92:3194-3200, 1995.
24. Anderson HV, McNatt J, Clubb FJ, et al: Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries. Circulation 104:2331-2337, 2001.
25. Madan M, Tcheng JE: Coronary intervention and glycoprotein IIb/IIIa integrin blockade. Coronary Art Dis 10:553-560, 1999.
26. Frangos SG, Chen AH, Sumpio B: Vascular drugs in the new millennium. J Am Coll Surg 191:76-92, 2000.
27. Alevriadou BR, Moake JL, Turner NA, et al: Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 81:1263-1276, 1993.
28. Turner NA, Moake JL, Kamat SG, et al: Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 91:1354-1362, 1995.
29. Wu CH, Chen YC, Hsiao G, et al: Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. Thromb Res 101:127-138, 2001.
30. Gimeno MJ, Gonzalez J, Rodriguez M, et al: Potential role of a new anti-beta3 integrin antibody in the development of intimal hyperplasia after vascular surgery: An in vitro smooth muscle cell model. Histol Histopathol 16:821-826, 2001.